Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

News Conference News TVT 2021

3M TAVR: Minimalist TAVI Pathway Saves Money

Todd Neale

July 26, 2021

News Conference News TVT 2020

Newer TAVR Devices Reassure in Failed Surgical Valves

Shelley Wood

June 20, 2020

News Conference News TVT 2019

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

Shelley Wood

June 14, 2019

Presentation TVT 2017

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Presenter: David J. Cohen, Jeffrey J. Popma, Robert O. Bonow

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Philippe Généreux

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: David J. Cohen, Jeffrey J. Popma, Nicolas M. Van Mieghem

June 16, 2017

Presentation TVT 2017

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

Presenter: David J. Cohen, Jeffrey J. Popma, Howard C. Herrmann

June 16, 2017

Presentation TVT 2017

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

Presenter: David J. Cohen, Jeffrey J. Popma, Martin B. Leon

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette III: Subset Analysis of Strokes

Presenter: David J. Cohen, Jeffrey J. Popma, A. Pieter Kappetein

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

Presentation TVT 2017

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

Presenter: David J. Cohen, Mark J. Russo, Adam Castano

June 16, 2017

Presentation TVT 2017

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Presenter: David J. Cohen, Mark J. Russo, Nir Uriel

June 16, 2017

Presentation TVT 2017

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Presenter: David J. Cohen, Mark J. Russo, Ran Kornowski

June 16, 2017

Presentation TVT 2017

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Presenter: David J. Cohen, Mark J. Russo, Suzanne V. Arnold

June 16, 2017

Presentation TVT 2017

Ineffective Endocarditis After TAVR: Cause for Concern?

Presenter: David J. Cohen, Mark J. Russo, Bernard Prendergast

June 16, 2017

Presentation TVT 2017

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Presenter: David J. Cohen, Mark J. Russo, Molly Szerlip

June 16, 2017

Presentation TVT 2017

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

Presenter: Ran Kornowski, Mark J. Russo, David J. Cohen

June 15, 2017

Advertisement

3M TAVR: Minimalist TAVI Pathway Saves Money

Newer TAVR Devices Reassure in Failed Surgical Valves

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

SURTAVI Vignette III: Subset Analysis of Strokes

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Ineffective Endocarditis After TAVR: Cause for Concern?

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content